Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Scandion Oncology Q1: All eyes on coming phase II data

CB

NE

Christian Binder

Niklas Elmhammer

Redeye comments on Scandion’s Q1 2021 report, which came without any surprises. CORIST phase II part 1 readout is just around the corner, as is preclinical data from Scandion’s immuno-oncology collaboration with Alligator Biosciences. Scandion is in a healthy financial position, with cash holdings to fund operations into 2023.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers